{"classes":[{"categories":[{"measurements":[{"comment":"Here, NA signifies that median and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"16.79","upperLimit":"NA","value":"NA"},{"comment":"Here, NA signifies that median and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"24.08","upperLimit":"NA","value":"NA"},{"comment":"Here, NA signifies that median and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"11.17","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from the date of the initial infusion of JNJ-68284528 to the date of first documented disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"MEDIAN","populationDescription":"mITT analysis set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre dose (Day 1) up to 45.2 months","title":"Phase 1b and Phase 2: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}